Cooley-Led Seattle Genetics Nets $552M In Follow-On
Cancer treatment developer Seattle Genetics Inc. said Monday that with Cooley LLP's guidance it raised $552 million in a follow-on offering, whose proceeds will help commercialize flagship drug Adcetris and expand...To view the full article, register now.
Already a subscriber? Click here to view full article